The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.
about
Evaluation of the Effect of Everolimus on Retinal Pigment Epithelial Cells and Experimental Proliferative Vitreoretinopathy.Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.Recent advances in uveal melanoma treatment.Targeting MDMX and PKCδ to improve current uveal melanoma therapeutic strategies.Selumetinib-based therapy in uveal melanoma patient-derived xenografts.
P2860
The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 March 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The mTOR inhibitor Everolimus ...... or efficacy in uveal melanoma.
@en
The mTOR inhibitor Everolimus ...... or efficacy in uveal melanoma.
@nl
type
label
The mTOR inhibitor Everolimus ...... or efficacy in uveal melanoma.
@en
The mTOR inhibitor Everolimus ...... or efficacy in uveal melanoma.
@nl
prefLabel
The mTOR inhibitor Everolimus ...... or efficacy in uveal melanoma.
@en
The mTOR inhibitor Everolimus ...... or efficacy in uveal melanoma.
@nl
P2093
P2860
P356
P1433
P1476
The mTOR inhibitor Everolimus ...... or efficacy in uveal melanoma.
@en
P2093
Ahmed Dahmani
Chloé Raymondie
David Gentien
Didier Decaudin
Estelle Frisch-Dit-Leitz
Fariba Némati
Guillaume Carita
Géraldine Liot
Marie Schoumacher
Nabil Amirouchene-Angelozzi
P2860
P304
23633-23646
P356
10.18632/ONCOTARGET.8054
P407
P577
2016-03-14T00:00:00Z